INT346571

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 0.96
Pain Relevance 0.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Sh3gl3) endosome (Sh3gl3) cytoplasm (Sh3gl3)
Anatomy Link Frequency
visceral 2
Sh3gl3 (Mus musculus)
Pain Link Frequency Relevance Heat
hypoalgesia 3 60.28 Quite High
peripheral neuropathy 9 5.00 Very Low Very Low Very Low
Spinal cord 6 5.00 Very Low Very Low Very Low
Neuropathic pain 6 5.00 Very Low Very Low Very Low
Peripheral nervous system 6 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
analgesia 3 5.00 Very Low Very Low Very Low
isoflurane 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 33 82.96 Quite High
Proteinuria 3 73.60 Quite High
Renal Failure 3 73.56 Quite High
Renal Disease 3 67.04 Quite High
Renal Insufficiency 3 66.64 Quite High
Chronic Renal Failure 3 64.48 Quite High
Death 3 61.92 Quite High
Hypoalagesia 3 60.28 Quite High
Polyuria 3 59.96 Quite High
Nociception 9 39.64 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Combined ERT and SRT is most effective at reducing GL-3 levels in tissues of the Fabry-Rag mouse
Negative_regulation (reducing) of Gene_expression (levels) of GL-3
1) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.06 Pain Relevance 0.06
Treating Fabry mice with eliglustat tartrate (SRT) reduced the urine GL-3 concentration to about 50% that of the untreated mice, mirroring the benefit observed in the visceral tissues (Figure 1).
Negative_regulation (reduced) of Gene_expression (concentration) of GL-3 in visceral
2) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.58 Pain Relevance 0
Overall, these results are consistent with an ability of eliglustat tartrate to inhibit (to some degree) the synthesis of glycosphingolipids such as GL-3, but because this inhibition is not complete and given the total absence of ?
Negative_regulation (inhibit) of Gene_expression (synthesis) of GL-3
3) Confidence 0.14 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2991350 Disease Relevance 0.32 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox